Clinical Trials Logo

Clinical Trial Summary

Intrauterine pathologies are currently treated by hysteroscopic resection. In this surgical procedure, the intrauterine pathology is resected by a transcervical approach in several fragments using a mono or bipolar cove after distension of the uterine cavity and by endoscopic control. The main risks of this surgery are: uterine perforation and OHIA (operative hysteroscopy intravascular absorption) syndrome. Hysteroscopic morcellators are new intrauterine devices, recently appeared on the French market.

In comparison to classical resectors, morcellators have several theoretical advantages:

- A smaller instrument diameter with potentially a lower risk of uterine perforation and cervical laceration during the dilatation procedure,

- The use of physiological serum, eliminating the risk of neurological toxicity of glycine,

- The risk of electrical accident is canceled (internal or external burns due to leakage current),

- A decreased risk of air embolism, due to the absence of bubbles' production,

- The instrument is always under visual control, the perforation risk by the active instrument is therefore very limited,

- The vision is not obscured by the fragments or by the bubbles,

- The treatment of pre-ostial pathologies, not always easy in classical resections, could be facilitated,

- the absence of thermal effect, and therefore a potentially lower endometrial aggression, is interesting in women with reproductive desire,

- Absence of chips management, limiting the entry and exit movements in the uterine cavity, improving the vision, reducing the infectious and traumatic risks, specially uterine perforation and air embolism,

- Morcellation could preserve tissues for histological analysis of possible malignancy (compared to techniques using heat, coagulation, vaporization),

- Easy learning in comparison to the time-consuming learning of classical hysteroscopic resection,

- Generated additional cost could be partly amortized by reducing operating time and complications.

It seemed useful to study this new technology.

The primary purpose was to compare the time of hysteroscopic treatment of uterine polyps between a hysteroscopic morcellator the UNIDRIVE S III / DrillCut-X II-GYN-Shaver (Integrated Bigatti Shaver IBS), Storz®, and a conventional resectoscope.

The secondary purposes were to compare the efficiency, complications and comfort of these techniques.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02472197
Study type Interventional
Source University Hospital, Strasbourg, France
Contact
Status Completed
Phase N/A
Start date September 2015
Completion date July 2018

See also
  Status Clinical Trial Phase
Recruiting NCT05049395 - HFNO Reducing the Incidence of Hypoxia for Hysteroscopy Sedated With Propofol N/A
Completed NCT02520414 - Symphion® System In-Office Study N/A
Completed NCT02126397 - Comparative Study of Endometrial Polypectomy Performed With Bipolar Electrode Versapoint and Laser Diode. A Randomised Controlled Trial. N/A
Not yet recruiting NCT02590666 - Endometrial Polypectomy Performed With Bipolar Electrode Versapoint vs Microscissors or Graspers N/A
Completed NCT01509313 - A Trial Comparing Morcellation With Electrical Resection for Removal of Uterine Polyps Phase 3